Despite an overall decrease in tobacco use, lung cancer (80–85% of which is non-small-cell lung cancer [NSCLC]) is still the leading cause of cancer death in both men and women worldwide. Annual low-dose CT screening of high-risk individuals has the potential to detect early-stage tumors, which can usually be successfully treated with a combination of surgery, radiotherapy and chemotherapy and, in some cases, targeted therapy. However, most patients with NSCLC still present with advanced or metastatic disease. For these patients, initial therapy is guided by the tumor’s molecular characteristics and patient’s performance status. Targeted therapies have significantly improved clinical outcomes and, for some patients with no targetable genetic alterations, immunotherapy has demonstrated significant overall survival benefit. This insightful guide is designed to bring you up to speed with the latest developments and is important reading for all health professionals and medical trainees working in this fast-moving field.
"synopsis" may belong to another edition of this title.
Seller: AwesomeBooks, Wallingford, United Kingdom
paperback. Condition: New. Fast Facts: Non-Small-Cell Lung Cancer Brand new item sourced directly from publisher. Packed securely in tight packaging to ensure no damage. Shipped from warehouse on same/next day basis. Seller Inventory # 1111-9783318070101
Quantity: 1 available
Seller: Majestic Books, Hounslow, United Kingdom
Condition: Used. Seller Inventory # 398570606
Quantity: 1 available
Seller: Books Puddle, New York, NY, U.S.A.
Condition: Used. Seller Inventory # 26397806513
Seller: Biblios, Frankfurt am main, HESSE, Germany
Condition: Used. Seller Inventory # 18397806523
Seller: Romtrade Corp., STERLING HEIGHTS, MI, U.S.A.
Condition: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide. Seller Inventory # ABBB-125475
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany
Taschenbuch. Condition: Neu. Neuware -Despite an overall decrease in tobacco use, lung cancer (80-85% of which is non-small-cell lung cancer [NSCLC]) is still the leading cause of cancer death in both men and women worldwide. Annual low-dose CT screening of high-risk individuals has the potential to detect early-stage tumors, which can usually be successfully treated with a combination of surgery, radiotherapy, and chemotherapy and, in some cases, targeted therapy. However, most patients with NSCLC still present with advanced or metastatic disease. For these patients, initial therapy is guided by the tumor's molecular characteristics and patient's performance status. Targeted therapies have significantly improved clinical outcomes and, for some patients with no targetable genetic alterations, immunotherapy has demonstrated significant overall survival benefit. This insightful guide is designed to bring you up to speed with the latest developments and is important reading for all health professionals and medical trainees working in this fast-moving field. Table of Contents: -Prevention and screening -Diagnosis and staging -Surgery -Radiotherapy -Systemic therapy in non-metastatic NSCLC -Systemic therapy in advanced-stage/metastatic disease without a molecular driver -Personalized treatment in advanced NSCLC -Oligometastatic disease and brain metastases 146 pp. Englisch. Seller Inventory # 9783318070101
Seller: AHA-BUCH GmbH, Einbeck, Germany
Taschenbuch. Condition: Neu. Neuware - Despite an overall decrease in tobacco use, lung cancer (80-85% of which is non-small-cell lung cancer [NSCLC]) is still the leading cause of cancer death in both men and women worldwide. Annual low-dose CT screening of high-risk individuals has the potential to detect early-stage tumors, which can usually be successfully treated with a combination of surgery, radiotherapy, and chemotherapy and, in some cases, targeted therapy. However, most patients with NSCLC still present with advanced or metastatic disease. For these patients, initial therapy is guided by the tumor's molecular characteristics and patient's performance status. Targeted therapies have significantly improved clinical outcomes and, for some patients with no targetable genetic alterations, immunotherapy has demonstrated significant overall survival benefit. This insightful guide is designed to bring you up to speed with the latest developments and is important reading for all health professionals and medical trainees working in this fast-moving field. Table of Contents: -Prevention and screening -Diagnosis and staging -Surgery -Radiotherapy -Systemic therapy in non-metastatic NSCLC -Systemic therapy in advanced-stage/metastatic disease without a molecular driver -Personalized treatment in advanced NSCLC -Oligometastatic disease and brain metastases. Seller Inventory # 9783318070101
Seller: Buchpark, Trebbin, Germany
Condition: Sehr gut. Zustand: Sehr gut | Seiten: 146 | Sprache: Englisch | Produktart: Bücher | Keine Beschreibung verfügbar. Seller Inventory # 38618247/2
Seller: Buchpark, Trebbin, Germany
Condition: Hervorragend. Zustand: Hervorragend | Seiten: 146 | Sprache: Englisch | Produktart: Bücher | Keine Beschreibung verfügbar. Seller Inventory # 38618247/1